Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 241 participants.

Also called NCT03434119

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 241 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03434119
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03434119. Randomized; no masking; primary purpose treatment. Start 2018-02-20 (actual); primary completion 2019-01-07 (actual). Results posted on 2020-01-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Acronym
LixiLan-D
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin glargine/Lixisenatide
Intervention (Drug)
Insulin glargine (HOE901)
Intervention (Drug)
Background therapy
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03434119
Content hash
efb0a0793dc4db9d1c28cd168c9b8c25f8aa7b4fc15495846d1df2220139b422